CRS-3123

Research use only, not for human use.

A novel diaryldiamine that inhibits bacterial methionyl-tRNA synthetases in Gram-positive bacteria as a novel agent to treat Clostridium difficile infection (CDI).

A novel diaryldiamine that inhibits bacterial methionyl-tRNA synthetases in Gram-positive bacteria as a novel agent to treat Clostridium difficile infection (CDI); inhibits de novo toxin production in high cell density, stationary phase cultures of C. difficile at 1 mg/L; demonstrates efficacy in the hamster model of CDI and is superior to vancomycin 0.5 mg/kg in CDI model.Bacterial Infection Phase 1 Clinical.

——

——

CRS3123 | REP 3123

GPCR/G Protein

Antibacterial

Antibacterial

Infection

Bacterial Infection

1013915-71-3

515.264

C19H21Br2N3O2S

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (194.84 mM)

BrC1=CC(Br)=C2OCC[C@H](C2=C1)NCCCNC3=CC(C4SC=CC4N3)=O

5-((3-(((R)-6,8-dibromochroman-4-yl)amino)propyl)amino)-3a,7a-dihydrothieno[3,2-b]pyridin-7(4H)-one

(-20℃)

With Ice Pack

≥ 2 years